PI3K/mTORC1/2 inhibitor PQR309 inhibits proliferation and induces apoptosis in human glioblastoma cells. 2020

Kun Yang, and Xiang-Jun Tang, and Feng-Fei Xu, and Jun-Hui Liu, and Yin-Qiu Tan, and Lun Gao, and Qian Sun, and Xiang Ding, and Bao-Hui Liu, and Qian-Xue Chen
Department of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China.

Glioblastoma (GBM) is the most common type of primary central nervous system tumor in adults, which has high mortality and morbidity rates, and short survival time, namely <15 months after the diagnosis and application of standard therapy, which includes surgery, radiation therapy and chemotherapy; thus, novel therapeutic strategies are imperative. The activation of the PI3K/AKT signaling pathway plays an important role in GBM. In the present study, U87 and U251 GBM cells were treated with the PI3K/mTORC1/2 inhibitor PQR309, and its effect on glioma cells was investigated. Cell Counting Kit‑8 assay, 5‑ethynyl‑2'‑deoxyuridine and colony formation assays revealed dose‑ and time‑dependent cytotoxicity in glioma cells that were treated with PQR309. Flow cytometry and western blotting revealed that PQR309 can significantly induce tumor cell apoptosis and arrest the cell cycle in the G1 phase. Furthermore, the expression levels of AKT, phosphorylated (p)‑AKT, Bcl‑2, Bcl‑xL, Bad, Bax, cyclin D1, cleaved caspase‑3, MMP‑9 and MMP‑2 were altered. In addition, the migration and invasion of glioma cells, as detected by wound healing, migration and Transwell invasion assays, exhibited a marked suppression after treating the cells with PQR309. These results indicated that PQR309 exerts an antitumor effect by inhibiting proliferation, inducing apoptosis, inducing G1 cell cycle arrest, and inhibiting invasion and migration in human glioma cells. The present study provides evidence supportive of further development of PQR309 for adjuvant therapy of GBM.

UI MeSH Term Description Entries
D009361 Neoplasm Invasiveness Ability of neoplasms to infiltrate and actively destroy surrounding tissue. Invasiveness, Neoplasm,Neoplasm Invasion,Invasion, Neoplasm
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D010766 Phosphorylation The introduction of a phosphoryl group into a compound through the formation of an ester bond between the compound and a phosphorus moiety. Phosphorylations
D002465 Cell Movement The movement of cells from one location to another. Distinguish from CYTOKINESIS which is the process of dividing the CYTOPLASM of a cell. Cell Migration,Locomotion, Cell,Migration, Cell,Motility, Cell,Movement, Cell,Cell Locomotion,Cell Motility,Cell Movements,Movements, Cell
D005909 Glioblastoma A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures. Astrocytoma, Grade IV,Giant Cell Glioblastoma,Glioblastoma Multiforme,Astrocytomas, Grade IV,Giant Cell Glioblastomas,Glioblastoma, Giant Cell,Glioblastomas,Glioblastomas, Giant Cell,Grade IV Astrocytoma,Grade IV Astrocytomas
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000076222 Mechanistic Target of Rapamycin Complex 1 An evolutionarily conserved multiprotein complex that functions as a cellular energy sensor and regulator of protein synthesis for cell growth and proliferation. It consists of TOR SERINE-THREONINE KINASES; REGULATORY-ASSOCIATED PROTEIN OF MTOR (RAPTOR); MLST8 PROTEIN; and AKT1 substrate 1 protein. The activity of the complex is regulated by SIROLIMUS; INSULIN; GROWTH FACTORS; PHOSPHATIDIC ACIDS; some amino acids or amino acid derivatives, and OXIDATIVE STRESS. TOR Complex 1,TORC1,Target of Rapamycin Complex 1,mTORC1,mTORC1 Complex,Complex, mTORC1
D000076225 Mechanistic Target of Rapamycin Complex 2 A multiprotein complex consisting of mTOR KINASE; MLST8 PROTEIN; rapamycin-insensitive companion of mTOR protein (RICTOR PROTEIN); and PRR5 (proline-rich protein 5). Like mTORC1, it also regulates cell growth and proliferation in response to growth factors but may not be as sensitive to nutrient availability and is insensitive to SIROLIMUS. In contrast to mTORC1, it can regulate the ACTIN CYTOSKELETON through RHO GTPASES to promote the formation of STRESS FIBERS. The mTORC2 complex also plays a critical role in AKT1 PROTEIN KINASE phosphorylation and activation. MTORC-2,TOR Complex 2,TORC2,Target of Rapamycin Complex 2,mTORC2,Complex 2, TOR
D000081082 Phosphoinositide-3 Kinase Inhibitors Agents that inhibit PHOSPHOINOSITIDE-3 KINASE activity. Phosphoinositide-3 Kinase Inhibitor,Inhibitor, Phosphoinositide-3 Kinase,Inhibitors, Phosphoinositide-3 Kinase,Kinase Inhibitor, Phosphoinositide-3,Kinase Inhibitors, Phosphoinositide-3,Phosphoinositide 3 Kinase Inhibitor,Phosphoinositide 3 Kinase Inhibitors
D015398 Signal Transduction The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway. Cell Signaling,Receptor-Mediated Signal Transduction,Signal Pathways,Receptor Mediated Signal Transduction,Signal Transduction Pathways,Signal Transduction Systems,Pathway, Signal,Pathway, Signal Transduction,Pathways, Signal,Pathways, Signal Transduction,Receptor-Mediated Signal Transductions,Signal Pathway,Signal Transduction Pathway,Signal Transduction System,Signal Transduction, Receptor-Mediated,Signal Transductions,Signal Transductions, Receptor-Mediated,System, Signal Transduction,Systems, Signal Transduction,Transduction, Signal,Transductions, Signal

Related Publications

Kun Yang, and Xiang-Jun Tang, and Feng-Fei Xu, and Jun-Hui Liu, and Yin-Qiu Tan, and Lun Gao, and Qian Sun, and Xiang Ding, and Bao-Hui Liu, and Qian-Xue Chen
November 2017, Oncology reports,
Kun Yang, and Xiang-Jun Tang, and Feng-Fei Xu, and Jun-Hui Liu, and Yin-Qiu Tan, and Lun Gao, and Qian Sun, and Xiang Ding, and Bao-Hui Liu, and Qian-Xue Chen
February 2016, Acta cirurgica brasileira,
Kun Yang, and Xiang-Jun Tang, and Feng-Fei Xu, and Jun-Hui Liu, and Yin-Qiu Tan, and Lun Gao, and Qian Sun, and Xiang Ding, and Bao-Hui Liu, and Qian-Xue Chen
October 2021, International journal of molecular sciences,
Kun Yang, and Xiang-Jun Tang, and Feng-Fei Xu, and Jun-Hui Liu, and Yin-Qiu Tan, and Lun Gao, and Qian Sun, and Xiang Ding, and Bao-Hui Liu, and Qian-Xue Chen
January 2015, International journal of clinical and experimental medicine,
Kun Yang, and Xiang-Jun Tang, and Feng-Fei Xu, and Jun-Hui Liu, and Yin-Qiu Tan, and Lun Gao, and Qian Sun, and Xiang Ding, and Bao-Hui Liu, and Qian-Xue Chen
April 2016, Oncology reports,
Kun Yang, and Xiang-Jun Tang, and Feng-Fei Xu, and Jun-Hui Liu, and Yin-Qiu Tan, and Lun Gao, and Qian Sun, and Xiang Ding, and Bao-Hui Liu, and Qian-Xue Chen
January 2021, Oxidative medicine and cellular longevity,
Kun Yang, and Xiang-Jun Tang, and Feng-Fei Xu, and Jun-Hui Liu, and Yin-Qiu Tan, and Lun Gao, and Qian Sun, and Xiang Ding, and Bao-Hui Liu, and Qian-Xue Chen
January 2015, Cancer cell international,
Kun Yang, and Xiang-Jun Tang, and Feng-Fei Xu, and Jun-Hui Liu, and Yin-Qiu Tan, and Lun Gao, and Qian Sun, and Xiang Ding, and Bao-Hui Liu, and Qian-Xue Chen
December 2018, Bioscience reports,
Kun Yang, and Xiang-Jun Tang, and Feng-Fei Xu, and Jun-Hui Liu, and Yin-Qiu Tan, and Lun Gao, and Qian Sun, and Xiang Ding, and Bao-Hui Liu, and Qian-Xue Chen
February 2013, Molecules (Basel, Switzerland),
Kun Yang, and Xiang-Jun Tang, and Feng-Fei Xu, and Jun-Hui Liu, and Yin-Qiu Tan, and Lun Gao, and Qian Sun, and Xiang Ding, and Bao-Hui Liu, and Qian-Xue Chen
January 2018, Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology,
Copied contents to your clipboard!